<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537104</url>
  </required_header>
  <id_info>
    <org_study_id>P-2020-551</org_study_id>
    <nct_id>NCT04537104</nct_id>
  </id_info>
  <brief_title>Remote Monitoring in Patients With Heart Failure</brief_title>
  <acronym>REM-HF</acronym>
  <official_title>Investigating Arrhythmias in a High-risk Population With Heart Failure Using Remote Monitoring (Coala Heart Monitor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coala Life, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective cohort study with consecutive enrollment of newly diagnosed heart&#xD;
      failure patients, investigating the prevalence and types of arrhythmias in this high-risk&#xD;
      population using non-invasive remote monitoring with the Coala Heart Monitor. Participants&#xD;
      are scheduled to use the Coala Heart Monitor twice daily or during symptoms (e.g. syncope,&#xD;
      presyncope, palpitations, chest discomfort, or shortness of breath) to record a thumb and&#xD;
      chest ECG over 3 months. Patient compliance with the recordings, self-reported health,&#xD;
      response to technology, and experience using the device will additionally be assessed by&#xD;
      self-developed questionnaires and the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>New-onset arrhythmias</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of newly diagnosed atrial fibrillation/atrial arrhythmias on patient-activated thumb and chest ECG recordings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>Week 8</time_frame>
    <description>Patient compliance with at least two daily recordings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient self-reported health</measure>
    <time_frame>3 months</time_frame>
    <description>Patient self-reported health assessed by KCCQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Patients' response to technology and experience using the device assessed by self-developed questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing recordings</measure>
    <time_frame>3 months</time_frame>
    <description>Where there are interpretations of arrhythmias on recordings, agreement of recordings with subsequent Holter monitoring will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent prescriptions</measure>
    <time_frame>3 years</time_frame>
    <description>Through linkage with nationwide health care databases, subsequent prescription patterns of diuretics and antithrombotic medication in patients with and without atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent implantations</measure>
    <time_frame>3 years</time_frame>
    <description>Through linkage with nationwide health care databases, subsequent implantation of cardiac devices in patients with and without atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent readmissions</measure>
    <time_frame>3 years</time_frame>
    <description>Through linkage with nationwide health care databases, subsequent readmissions to hospital in patients with and without atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Through linkage with nationwide health care databases, all-cause mortality in patients with and without atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Through linkage with nationwide health care databases, cardiovascular mortality in patients with and without atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admissions for worsening heart failure</measure>
    <time_frame>3 years</time_frame>
    <description>Through linkage with nationwide health care databases, and admission for worsening heart failure in patients with and without atrial fibrillation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coala Heart Monitor</intervention_name>
    <description>ECG monitoring</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed heart failure patients &gt; 18 years of age from heart failure clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Owns or has access to a smartphone&#xD;
&#xD;
          -  Newly diagnosed moderate to severe heart failure (NYHA II-IV and left ventricular&#xD;
             ejection fraction ≤ 40%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Earlier atrial fibrillation/atrial flutter with indication for oral anticoagulant&#xD;
             (OAC) treatment&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Cardiac resynchronization device&#xD;
&#xD;
          -  Indications for OAC treatment (also low molecular weight heparin) due to atrial&#xD;
             arrhythmias, mechanical heart valve, deep vein thrombosis, or pulmonary embolism.&#xD;
&#xD;
          -  Expected survival ≤ 6 months&#xD;
&#xD;
          -  Absolute contraindications for starting OAC treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Morten Kjøbek Lamberts, MD, PhD</last_name>
    <phone>+4522434186</phone>
    <email>morten.kjoebek.lamberts@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Herlev &amp; Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Kjøbæk Lamberts, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Morten Lamberts</investigator_full_name>
    <investigator_title>Associate Professor and Research Director</investigator_title>
  </responsible_party>
  <keyword>arrhythmias</keyword>
  <keyword>heart failure</keyword>
  <keyword>remote monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

